• LAST PRICE
    3.6500
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.5000/ 6
  • Ask / Lots
    3.5500/ 10
  • Open / Previous Close
    0.0000 / 3.6500
  • Day Range
    ---
  • 52 Week Range
    Low 2.8935
    High 4.7500
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Tuesday's close: 3.61
TimeVolumeGNFT
09:54 ET20003.5972
11:45 ET1003.59
02:51 ET4003.65
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGNFT
Genfit SA
179.2M
-4.9x
---
United StatesCLLS
Cellectis SA
192.5M
-1.4x
---
United StatesCGEN
Compugen Ltd
227.4M
-11.8x
---
United StatesCAPR
Capricor Therapeutics Inc
212.6M
-7.8x
---
United StatesFHTX
Foghorn Therapeutics Inc.
267.3M
-2.7x
---
United StatesACRS
Aclaris Therapeutics Inc
89.4M
-1.0x
---
As of 2024-03-28

Company Information

Genfit SA is a France-based biopharmaceutical company that specializes in the development of medicines for the prevention and treatment of diabetes and related disorders. The Company is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The Company targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

Contact Information

Headquarters
Parc Eurasante 885 avenue Eugene AvineeLOOS, France 59120
Phone
---
Fax
---

Executives

Chairman of the Board
Jean-Francois Mouney
Independent Vice Chairman of the Board
Xavier Guille Des Buttes
Chief Executive Officer
Pascal Prigent
Chief Financial Officer
Thomas Baetz
Chief Operating Officer
Pascal Caisey

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$179.2M
Revenue (TTM)
$32.2M
Shares Outstanding
49.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.08
EPS
$-0.74
Book Value
$2.05
P/E Ratio
-4.9x
Price/Sales (TTM)
5.6
Price/Cash Flow (TTM)
---
Operating Margin
-108.38%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.